Lead Product(s) : CT7439
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Carrick Treats First Patient in Phase 1 Trial of CT7439 (CDK12/13 Inhibitor)
Details : CT7439 is a best-in-class novel cyclin-dependent kinase 12/13 inhibitor, which is being evaluated for the treatment of multiple neoplasms.
Product Name : CT7439
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : CT7439
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Samuraciclib,Vepdegestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Carrick Doses First Patient in Phase 1b/2 Trial of Samuraciclib in Breast Cancer
Details : CT7001 (samuraciclib) is a first-in-class oral CDK7 inhibitor evaluated with ARV-471 (vepdegestrant) for ER+, HER2- metastatic breast cancer treatment.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Samuraciclib,Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Samuraciclib,Elacestrant DiHCl
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CT7001 (samuraciclib) is an oral and first-in-class inhibitor of CDK7, and the Menarini Group's (Menarini) oral selective estrogen receptor degrader (SERD), elacestrant, in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2023
Lead Product(s) : Samuraciclib,Elacestrant DiHCl
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Arch Ventures
Deal Size : $25.0 million
Deal Type : Series C Financing
Carrick Therapeutics Closes Series C Financing
Details : The Company intends to use the proceeds to fund ongoing and planned CT7001 (samuraciclib) clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Arch Ventures
Deal Size : $25.0 million
Deal Type : Series C Financing
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $35.0 million
Deal Type : Financing
Carrick Therapeutics Announces $35 Million Investment from Pfizer
Details : CT7001 (samuraciclib), an oral CDK7 inhibitor, is a promising therapeutic strategy in cancer, as CDK7 regulates transcription of cancer-causing genes and promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $35.0 million
Deal Type : Financing
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Agreement
Carrick Therapeutics Announces $35 Million Investment from Pfizer
Details : Under the terms of the agreement, Pfizer will provide global development capabilities and expertise to support Carrick’s Phase 2 study of CT-7001 (samuraciclib) in combination with fulvestrant for CDK4/6i-resistant HR+, HER2- advanced breast cancer.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Samuraciclib inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2021
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cavrotolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The fast track designations for cavrotolimod has been granted for two development programs: cavrotolimod in combination with anti-PD-1 therapy for metastatic Merkel cell carcinoma and cavrotolimod in combination with anti-PD-(L)1) therapy in cutaneous sq...
Product Name : AST-008
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Cavrotolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clinical data on samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, regulates the transcription of cancer-causing genes,support its continued development in breast cancer.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2021
Lead Product(s) : Samuraciclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Samuraciclib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Carrick Therapeutics is going to present two posters (i) Study of samuraciclib in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (ii) First in human, modular study of samuraciclib in advanced ...
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2021
Lead Product(s) : Samuraciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable